ClinicalTrials.gg
RecruitingNCT07787273Updated Aug 26, 2026

Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of Interferon-γ and Camrelizumab in Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy and Camrelizumab, sponsored by Hefei Cancer Hospital of the Chinese Academy of Sciences. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Hefei Cancer Hospital of the Chinese Academy of Sciences · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2026, registered Aug 2026).
  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma — 5 open to participants now, 7 under way, 2 of them phase 3. camrelizumab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
6th of 20
84 · median 46
Started
2026
with 2 others
Phase 2
13 of 20
2 open now
Registered
20th of 20
by date
Lead sponsor
1 of 20
Hefei Cancer Hospital of the Chinese Academy of Sciences

Among the 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma, this one is the 6th largest by planned enrollment, is one of 3 that started in 2026, is one of 13 in phase 2, and was the 20th registered.

Esophageal Squamous Cell Carcinoma

676 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 267 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

5 of the 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing camrelizumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of interferon-gamma combined with camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma. Based on previous mechanistic research and preliminary clinical data, this trial intends to generate high-level evidence for this therapeutic strategy, which may improve the treatment landscape for patients with locally advanced esophageal squamous cell carcinoma.

03

Conditions studied

  • Locally Advanced Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • Camrelizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged >= 18 years;
  2. confirmed esophageal squamous cell carcinoma (ESCC), clinical stage cT1b-3, N+, M0;
  3. (ECOG) performance status 0-1;
  4. Expected overall survival > 6 months;
  5. Adequate bone marrow, hepatic, renal, coagulation, and thyroid function.

Exclusion criteria

Exclusion Criteria:

  1. Active disease;
  2. Requirement for systemic therapy;
  3. to any study drug;
  4. Uncontrolled significant organ disease (e.g., cardiac, pulmonary, hepatic, renal) or active infection;
  5. Pregnant or lactating female.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Interferon-γ combined with camrelizumab and neoadjuvant chemotherapy

    Drug: Interferon-γ · Drug: Camrelizumab

Interventions

  • DrugInterferon-γ

    1,000,000 IU administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.

  • 200 mg administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.

06

What researchers measure

Primary outcomes

  1. Pathological complete response rate

    The proportion of patients achieving pathological complete response (absence of viable tumor cells in primary lesion and regional lymph nodes) evaluated by pathological examination of surgical specimens.

    Time frame: At the time of surgical resection.

Secondary outcomes

  1. Objective Response Rate

    The proportion of participants with confirmed complete response (CR) or partial response (PR) assessed per RECIST 1.1.

    Time frame: At the end of Cycle 2, Cycle 4, (each cycle is 21 days).

  2. Progression-free survival

    Time from enrollment to disease progression (per RECIST 1.1) or death from any cause, whichever occurs first.

    Time frame: From date of enrollment until the date of first documented progression or death from any cause, whichever came first, assessed up to 24 months.

  3. Overall Survival

    Follow-up via outpatient visits or telephone interviews; defined as time from enrollment to death from any cause.

    Time frame: From date of enrollment until death from any cause, assessed up to 24 months.

  4. Duration of Response

    Time from first observation of confirmed CR or PR to disease progression or death from any cause, assessed per RECIST Version 1.1.

    Time frame: From the date of first documented confirmed response until disease progression or death from any cause, assessed up to 24 months.

Other outcomes

  1. Adverse events

    Adverse events graded by CTCAE Version 5.0; safety follow-up within 90 days after last study drug administration to monitor outcomes of adverse events.

    Time frame: Baseline up to 90 days after last study treatment.

07

Study locations

2 of 2 sites recruiting
  • Hefei Cancer Hospital, Chinese Academy of Sciences
    Hefei, Anhui, China
    Recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 153 non-industry phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 24 months is below that.

Counting every sponsor, half of 173 studies reached it within 40 months; a quarter within 28 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 26, 2026
StartActual
Mar 20, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07787273
Lead sponsor
Hefei Cancer Hospital of the Chinese Academy of Sciences
Responsible party
Sponsor
First posted
Aug 26, 2026
Start date
Mar 20, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 26, 2026

Study contacts

Hongzhi Wang
Contact
wanghz@hfcas.ac.cn
+86 551 6589 5180
Hongzhi Wang
study chair · Hefei Cancer Hospital, Chinese Academy of Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion